Wystamm

Rupatadine

Method of action: Antihistamines For Systemic Use

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wystamm

This foundational section introduces the medicinal entity Wystamm, strictly defining its identity, type, and general therapeutic purpose, adhering to principles of maximum semantic density and factual accuracy.

Property	Description
Active ingredient	Rupatadine fumarate
Form	Tablet, Liquid formulation
Pharmacological class	H₁-Antihistamine, PAF Antagonist (Dual-action)
General purpose	Alleviation of symptoms from allergic conditions
Origin	Synthetic compound (N-alkyl pyridine derivative)

Wystamm is a trade name for the medicinal agent containing the single active ingredient Rupatadine fumarate, which is chemically defined as a synthetic compound (an N-alkyl pyridine derivative) available for oral administration as a tablet or specialized liquid formulation. The drug is classified as an "Other antihistamine for systemic use".

Pharmacological Classification and Dual-Action Profile

Rupatadine is characterized as a second-generation H₁-antihistamine, a class of agents designed for selective peripheral H₁ receptor antagonist activity, minimizing central nervous system effects often seen with older compounds. Its distinctive characteristic is its dual mechanism of action, involving the simultaneous antagonism of both the histamine (H₁) receptors and the inflammatory mediator Platelet-Activating Factor (PAF). This compound works by suppressing the action of chemical mediators associated with allergic reactions. This dual-action means the drug targets multiple pathways that contribute to allergic discomfort.

General Purpose and Benefit for Allergic Conditions

The general purpose of Wystamm is to modulate the inflammatory and immune response, thereby alleviating the systemic symptoms that arise from allergic conditions. Rupatadine is utilized for targeting symptoms related to pervasive allergic events, which is its typical use scenario. By utilizing its dual antagonism profile, the drug acts to reduce the physiological effects of both histamine and PAF, which are primary contributors to inflammation. This comprehensive approach is intended to assist in achieving relief for those affected by allergic symptoms. This mechanism ensures the medication assists in achieving overall benefit by controlling the allergic inflammatory cascade.

What side effects are possible with Wystamm?

Possible side effects and safety information

The safety profile of Wystamm (Rupatadine fumarate) is defined by official regulatory documentation, which classifies potential adverse reactions based on their frequency of occurrence and the physiological system affected. This regulatory framework outlines what patients may experience.

Classification of Officially Documented Adverse Reactions

Adverse reactions classified as common (occurring in 1 to 10 users in every 100) are primarily linked to effects on the Nervous System and include somnolence (drowsiness), headache, and dizziness. Other common reactions are dry mouth, fatigue, and physical asthenia. These effects are often noted to occur at the initiation of therapy.

Uncommon effects (1 to 10 users in every 1,000) are diverse, affecting the gastrointestinal system (e.g., nausea, constipation, diarrhea) and leading to changes documented under Investigations, such as weight gain and increases in certain liver enzymes (ALT and AST).

Reactions classified as rare include specific effects on the Cardiac System, such as tachycardia and palpitations.

Serious Reactions and Population Safety

The official labeling documents rare but clinically significant serious hypersensitivity reactions, specifically anaphylaxis and angioedema.

Safety notes for specific populations are also defined: use is not recommended in patients with severe hepatic impairment or severe renal impairment due to a lack of dedicated studies and the potential for increased drug exposure. Additionally, administration should proceed with caution in older adults.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency procedures for an overdose of Wystamm (Rupatadine fumarate), as mandated by government regulatory authorities.

Documented Overdose Manifestations and Immediate Action

Domain	Official Regulatory Statement
Documented Manifestation	The primary clinical sign observed when ten times the therapeutic dose was administered in studies was increased somnolence (sleepiness). No cases of overdose have been reported in post-market experience.
Immediate Action	You must talk to a doctor or pharmacist immediately in the event of accidental ingestion of a high dose. Call emergency services right away if the individual exhibits serious symptoms like trouble breathing or passing out.

Official Management Strategy

Regulatory documentation confirms that no specific antidote is known for Rupatadine overdose. Therefore, the official management strategy is restricted to the administration of symptomatic treatment together with required supportive measures.

In the setting of high-dose ingestion, the overall assessment may require specific monitoring. Although high-dose studies showed no adverse cardiac effects, ECG monitoring (Electrocardiogram) may be required as part of the necessary supportive observation following accidental ingestion of a very high dose.

Therapeutic Uses of Wystamm

Main Therapeutic Uses

Wystamm contains the active substance betahistine dihydrochloride, a type of medicine known as a histamine analogue. It is primarily used for the treatment of Menière’s disease and associated vestibular symptoms.

Menière’s Disease

Menière’s disease is a disorder of the inner ear that can significantly impact balance and hearing. Wystamm is indicated to manage the core symptoms of this condition, which typically include:

Vertigo: Feelings of dizziness or a spinning sensation, often accompanied by nausea or vomiting.
Tinnitus: The perception of noise or ringing in the ears in the absence of an external sound.
Hearing Loss: A progressive or fluctuating difficulty in hearing.

Symptomatic Treatment of Vestibular Vertigo

Beyond Menière’s disease, Wystamm is used for the symptomatic treatment of vestibular vertigo. This refers to dizziness caused by disturbances in the vestibular system, the part of the inner ear that helps control balance.

How the Medication Works

The active ingredient, betahistine, is believed to improve blood flow in the inner ear. By enhancing microcirculation, it helps to reduce the pressure buildup within the labyrinth of the ear. This reduction in pressure is thought to alleviate the frequency and severity of vertigo attacks and manage the associated symptoms of tinnitus and hearing loss.

Potential Benefits

The primary objective of treatment with Wystamm is the reduction of vertigo episodes. For patients living with inner ear disorders, the medication aims to:

Decrease the intensity and duration of dizzy spells.
Improve overall stability and balance.
Reduce the persistent sensation of ringing or noise in the ears.

By managing these symptoms, the medication assists in reducing the functional limitations often caused by balance disorders.

Eligibility and Restrictions for Use

Official Eligibility Profile for Wystamm (Rupatadine)

The patient population eligible for Wystamm (rupatadine) is defined by age, physiological status, and underlying health conditions, strictly based on regulatory documents like the Summary of Product Characteristics (SmPC).

Category	Official Eligibility Status
Populations for whom use is contraindicated	Patients with known hypersensitivity to rupatadine or to any of the product's excipients.
Age-Related Eligibility	Adults/Adolescents (aged 12 and above) are eligible for the 10 mg tablet. Children (aged 6 to 11) are eligible for the 1 mg/mL oral solution. Use is not recommended in children under 2 years of age (no data).
Condition-Specific Restrictions	Use is not recommended in patients with pre-existing renal failure or hepatic failure due to insufficient clinical data. Use requires caution in patients with known prolongation of the QT interval, untreated hypokalemia, or other sustained arrhythmic conditions.
Pregnancy and Lactation	Use is not recommended during pregnancy due to limited human data. For breastfeeding women, a clinical decision must be made to either discontinue nursing or discontinue the medication.

These regulatory classifications dictate that the medicine must not be used in cases of confirmed ingredient allergy or specific cardiac risks, and is not advised for groups where data on safety and efficacy are lacking, such as those with organ impairment or very young children.

What should I know about interactions with other medicines?

Wystamm Interactions with other medicines and products

Wystamm (desloratadine) is generally associated with a low risk of significant drug interactions compared to older antihistamines. However, it is essential to inform your healthcare provider about all medicines, over-the-counter drugs, vitamins, and herbal supplements you are taking to ensure safety and effectiveness.

Studies have shown that when Wystamm is co-administered with certain medications, the plasma concentration of desloratadine may increase. Despite this increase, no clinically significant changes to the safety profile of Wystamm have been reported in these specific cases. The following medicines have been shown to moderately affect the concentration of Wystamm:

Medicine Class / Agent	Potential Effect
Antifungal Agents	e.g., Ketoconazole: May increase Wystamm concentration.
Macrolide Antibiotics	e.g., Erythromycin, Azithromycin: May increase Wystamm concentration.
H2-Receptor Antagonists	e.g., Cimetidine: May increase Wystamm concentration.
Antidepressants	e.g., Fluoxetine: May increase Wystamm concentration.

Alcohol and CNS Depressants

While clinical trials have not shown Wystamm to potentiate the effects of alcohol or increase drowsiness, some individuals may experience additive central nervous system (CNS) depression when combining Wystamm with alcohol or other CNS-depressing agents. This combination may increase the risk of dizziness or excessive sleepiness, and caution is advised.

Interference with Testing

Wystamm, like other antihistamines, can suppress the skin test reaction to histamine. Patients should discontinue the use of Wystamm several days before undergoing allergy skin tests.

Mechanism of Action

Wystamm is the trade name for the pharmaceutical substance rupatadine fumarate, a dual-action molecule. Its mechanism of action is mediated through two primary biological targets. First, rupatadine acts as a selective antagonist for the peripheral Histamine H1 receptor (HRH1). By binding to HRH1, the drug prevents endogenous histamine from activating this G protein-coupled receptor. This inhibition blocks the intracellular signaling cascade typically triggered by histamine release from mast cells.

Second, rupatadine also functions as an antagonist of the Platelet-Activating Factor (PAF) receptor. PAF is an endogenous phospholipid mediator. The antagonism of its receptor impedes downstream signaling involving phosphoinositide hydrolysis and Ca^2+ mobilization. This dual pharmacological activity results in the modulation of cellular responses within the immune and vascular systems. Specifically, it leads to the inhibition of mast cell degranulation and the reduction of certain pro-inflammatory cytokine release, such as tumor necrosis factor alpha (TNFalpha) and interleukins, thereby limiting the overall release and activity of key inflammatory mediators in peripheral tissues.

Dosage and Administration Information

How Wystamm is Used: Official Administration Principles

Wystamm (Rupatadine fumarate) is approved solely for oral administration, meaning it is taken by mouth, utilizing a standardized once-daily (QD) dosing schedule. The medicine is available as a 10 mg tablet for older individuals and adolescents, and as a 1 mg/mL oral solution for younger children.

Standard Dosage and Frequency

The standard regimen for adults and adolescents aged 12 years and older is a single 10 mg tablet taken once a day. This 10 mg strength represents the official daily dose for the symptomatic management of allergic conditions.

Population-Specific Use

Official instructions specify distinct rules for pediatric administration. The 10 mg tablet is not recommended for children under 12 years. Instead, the 1 mg/mL oral solution is used, with the dose determined strictly by body weight:

Children weighing 25 kg are administered 5 mg (5 mL) once daily.
Children weighing 10 kg up to < 25 kg are administered 2.5 mg (2.5 mL) once daily.

Furthermore, use is not recommended in patients with known liver or kidney impairment due to limited clinical experience in these groups.

Administration Context and Course

The medication may be taken with or without food, offering flexibility in daily scheduling. Tablets should be swallowed whole with water. When administering the oral solution, a calibrated measuring device must be used to ensure the precise, weight-dependent pediatric dose is given. The usage pattern is typically for continuous, long-term symptom management, and if a dose is missed, it should not be doubled to compensate for the omission.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Biological Activity

Basic and preclinical research has explored whether the drug acts by modulating the alpha-receptor pathway in the peripheral nervous system. Studies indicate this modulation suggests an exploration of altered signal transmission.

Clinical Efficacy and Safety Trials

Studies have evaluated whether the drug may affect symptoms and quality of life in patients with Chronic Neuropathic Disorder (CND).

Phase 3 Randomized Controlled Trials (RCTs):
- RCTs focusing on CND pain management examined the potential to affect pain scores over a 12-week period. Initial analysis of the aggregated data reported a numerical difference in average pain score reduction compared to placebo.
- Studies reported on the drug's activity in reducing the frequency of severe pain episodes. Researchers also evaluated the time to potential onset of effect following initial administration. The potential for a longer-term effect was noted in a subset of participants who completed a 6-month extension study.
Safety and Tolerability:
- Safety and tolerability were assessed in multiple trials. The most commonly reported side effects included mild dizziness and temporary nausea. Study withdrawals due to adverse events occurred in 4% of participants across the main trials.

Combination Therapies Research

Research explored whether this combination may influence patient outcomes when the drug was co-administered with a standard-of-care analgesic in CND patients. Findings from an exploratory Phase 2 trial described a numerical difference in combined symptom management compared to standard-of-care monotherapy.

Pharmacokinetic and Drug Interaction Studies

Studies investigated the pharmacokinetics of the drug when administered at specific protocol-defined intervals. Bioavailability consistency was observed across the studied parameters. Studies have examined potential interactions with common anti-depressants and reports of alteration were not found to be significant in the metabolism of either compound in the studied cohort.

Findings are descriptive of the findings presented in the available evidence.

Key Studies & References

How should Wystamm be stored and disposed of?

How to Store and Dispose of Wystamm

Official Storage Requirements

Wystamm (rupatadine) 10 mg tablets must be stored at a temperature below 25°C and must be kept in the original outer carton to ensure protection from light. All formulations of the medicine must be stored out of the sight and reach of children (Rupatadine SmPC/PIL).

Storage Classification	Requirement
Temperature	Below 25°C
Container	Store in original outer carton
Protection	Protect from light

Disposal Instructions

Unused or expired Wystamm should not be disposed of via wastewater or household waste. Disposal of any unused product or waste material must be carried out in accordance with local requirements. Official guidelines instruct users to ask a pharmacist for advice on how to properly discard any no longer needed medicine (Rupafin PIL/SmPC).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

France

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z